(Reuters Health) – Aggressive use of crimson-cell transfusion for very-low-initiating-weight newborns with anemia would not toughen survival and fails to stem neurodevelopmental impairment by age 2, clinical doctors in the serve of a brand fresh encounter reported Wednesday. The TOP…